Case Report

Additional Evidence of the Abuse Potential of Quetiapine

Authors: Roy R. Reeves, DO, PhD, James C. Brister, MD

Abstract

Quetiapine is an atypical antipsychotic agent approved by the FDA for the treatment of schizophrenia, acute mania, and bipolar depression. Recently, reports of medication abuse, particularly intranasal and IV abuse, have been described. Three cases of oral misuse of quetiapine are presented and clinical implications are discussed. Clinicians should exercise caution when prescribing quetiapine to patients at risk for substance abuse.


Key Points


* Quetiapine is an atypical antipsychotic agent approved by the FDA for the treatment of schizophrenia, acute mania, and bipolar depression.


* Quetiapine may have sedating and anxiolytic effects in some patients.


* Clinicians should exercise caution when prescribing quetiapine to patients at risk for substance abuse.

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Pierre JM, Shnayder I, Wirshing DA, et al. Intranasal quetiapine abuse. Am J Psychiatry 2004;161:1718.
 
2. Hussain MZ, Waheed W, Hussain S. Intravenous quetiapine abuse. Am J Psychiatry 2005;162:1755–1756.
 
3. Pinta ER, Taylor RE. Quetiapine addiction? Am J Psychiatry 2007;164:174–175.
 
4. Waters BM, Joshi KJ. Intravenous quetiapine-cocaine use (‘Q-ball’). Am J Psychiatry 2007;164:173–174.
 
5. Calabrese JR, Kech PE, Macfadden W, et al. A randomized, double-blind placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351–1360.
 
6. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression. J Clin Psychopharmacol 2006;26:600–609.
 
7. Brawman-Mintzer O, Nietert PJ, Rynn MA, et al. Quetiapine monotherapy in patients with GAD. Presented at the American Psychiatric Association Annual Meeting, May, 2006, Toronto, Canada, Abstract NR634.
 
8. Adityanjee Schulz SC. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry 2002;63(Suppl 13):32–38.